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ABSTRACT
Cord blood (CB) progenitor cells are increasingly used for transplantation in children because of the lower risk
of graft-versus-host disease compared with unrelated bone marrow and comparable rates of disease-free
survival. There is concern that CB might carry a higher risk of opportunistic infections. Human herpesviruses
(HHV) are common pathogens in transplant recipients. CB donors are routinely tested for the presence of
anti-cytomegalovirus (CMV) immunoglobulin M to reduce the risk of collecting CMV-infected CB. To assess
the incidence of  and HHV infection of CB collected under standard procedures, we tested 362 CB samples
for the presence of CMV; HHV-6, -7, and -8; and Epstein-Barr virus DNA by polymerase chain reaction.
HHV-6 DNA was found in 2 samples, yielding an incidence of 0.55% (95% confidence interval, 0.1%-2%).
None of the other viral DNAs was found, resulting in a 95% confidence interval of 0% to 1% for the incidence
of CMV, Epstein-Barr virus, HHV-7, and HHV-8. Because the seroprevalence of HHV-8 among the CB
donors in this study was only 4%, these findings cannot be extended to HHV-8–endemic areas. Our data show
that screening prospective CB donors with anti-CMV immunoglobulin M practically eliminates the risk of CB
CMV transmission, but HHV-6 warrants CB testing by polymerase chain reaction.
© 2005 American Society for Blood and Marrow Transplantation
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UNTRODUCTION
Umbilical cord blood (CB)–derived progenitor cells
re increasingly used to restore hematopoiesis in patients
ho require bonemarrow transplantation. Since the ﬁrst
B transplantation was performed by Gluckman et al. in
988 [1], more than 3000 patients worldwide have re-
eived related or unrelated CB transplants for a variety of
alignant and nonmalignant diseases [2,3]. The event-
ree survival rates reported thus far are comparable to
esults achieved after unrelated allogeneic marrow trans-
lantation. Moreover, there are many reports of less
raft-versus-host disease than with marrow transplanta-
ions [4,5], particularly in pediatric patients. CB donors
re typically screened for themost common blood-borne
athogens and disqualiﬁed if there is serologic evidence
f infection with Treponema pallidum, human immuno-
eﬁciency virus (HIV)–1 and -2, human T lymphotropic
iruses 1 and 2, hepatitis B (HBV) and C viruses, or
ecently acquired cytomegalovirus (CMV).In addition to CMV, other  and  human her- t
B&MTesviruses (HHV) have the potential of establishing
nfection of circulating mononuclear cells and con-
aminating the CB infusion. Severe disease conse-
uent to hematopoietic cell-associated transmission of
HV-6 [6], HHV-8 [7], and Epstein-Barr virus
EBV) [8,9] has been recorded. Although congenital
BV infection is extremely rare [10], in utero trans-
ission of HHV-6 and -8 has been reported at rates
arying from 1% to 1.6% [11,12] and 0.4% [13],
espectively. A comprehensive literature review failed
o reveal any published studies of congenital HHV-7
nfection. In this study, we examined the prevalence of
and  HHV DNA in banked CB samples.
ATERIALS AND METHODS
B Samples
Frozen CB was obtained from the CB bank at the
niversity of Colorado Health Sciences Center. Po-ential donors, identiﬁed and enrolled according to
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3he local investigational review board–approved pro-
ocol, were tested for the presence of anti–HIV-1 and
2, HIVP24, human T lymphotropic virus 1 and 2,
epatitis C virus, and HBV immunoglobulin (Ig)G
ntibodies; HBV surface antigen; anti-CMV IgM an-
ibodies; and rapid plasma reagin. Of these, CMV IgM
creening is speciﬁc to our blood bank and may not be
erformed at other centers. CB were collected from
he donors with negative results for all these tests. In
ddition, aliquots of whole and volume-reduced CB,
s well as serum from the CB and the mother, were
rozen for subsequent testing and screening out in-
ected units. When a candidate CB recipient was iden-
iﬁed, one of the frozen aliquots was further tested for
MV, parvovirus B 19, and HIV-1 by polymerase
hain reaction (PCR).
HV DNA Measurements
Multiplex PCR was performed by using the prim-
rs and probes previously validated in our laboratory
14-17] (Table 1). DNA was extracted from 200 L of
ryopreserved whole blood with QIAamp DNA puri-
cation columns (Qiagen, Valencia, CA). The multi-
lex PCR was performed in 50 L of ﬁnal volume
ontaining 20 L of extracted DNA, 1.25 U of PfuI
Stratagene, La Jolla, CA), 200 mol/L of each of 4
eoxynucleoside triphosphates, and 0.5 mol/L of
ach of the biotinylated primers in PfuI buffer (Strat-
gene). The samples were ampliﬁed for 45 cycles. The
mpliﬁed DNA was allowed to bind to capture probes
0.5 g/mL in 1 mol/L ammonium acetate) previous-
y immobilized onto 96-well enzyme immunoassay
lates. Bound amplicon was detected with streptavi-
in/horseradish peroxidase (R&D Systems, Minneap-
lis, MN) and tetranitrotetrazolium blue colorimetric
ubstrate (R&D Systems). The optical density (OD)
as measured at 450 nm with an enzyme immunoas-
ay reader. A sample with an OD0.6 was considered
ositive for the presence of the DNA of interest. This
ethod has a limit of detection (LOD) of 2 copies
er reaction tube of each of the targeted viral DNAs.
his corresponds to a LOD of 1 copy per 103 CB
ononuclear cells. If infected cells contained only 1
able 1. Sequences of Primers and Probes Used for HHV  and  Mu
Virus Primer Pair 5= 3 3=
MV GGC AGC TAT CGT GAC TGG GA
GAT CCG ACC CAT TGT CTA AG
BV GTC AAC CAA CAA GGA CAC AT
CAC CAC CTT GTT TTG ACG GG
HV-6 AAG CTT GCA CAA TGC CAA AAA ACA G
CTC GAG TAT GCC GAG ACC CCT AAT C
HV-7 TAT CCC AGC TGT TTT CAT ATA GTA AC
GCC TTG CGG TAG CAC TAG ATT TTT TG
HV-8 TCC GTG TTG TGT ACG TGG AG
AGC CGA AAG GAT TCC ACC ATopy of viral DNA, then the LOD for infected cells t
6ould be 0.1% of the CB mononuclear cells. How-
ver, because infected cells typically contain multiple
opies of viral DNA, a more accurate LOD is approx-
mately 0.01% of infected cells. Positive and negative
ontrols were included in each run. The runs were
onsidered valid if the absorbance of the negative
ontrol was 0.3 and that of the positive control was
1.0. Multiplex PCR–positive results were conﬁrmed
y a single PCR consisting of ampliﬁcation and
outhern blot detection as previously described [14-
7].
HV Serology
The IgG antibodies anti-CMV, anti-EBV, anti-
HV-6, and anti-HHV-8 were detected with commer-
ially available enzyme-linked immunosorbent assay kits
ccording to the manufacturers’ instructions (CMV,
iamedix, Miami, FL; EBV, Sigma, St. Louis, MO;
HV-6 and -8, Advanced Biotechnologies Inc., Colum-
ia, MD). Anti-HHV-7 IgG antibodies were measured
ith HHV-7 puriﬁed viral antigen (Advanced Biotech-
ologies Inc.), anti-human IgG/horseradish peroxidase
onjugate (Sigma), and tetranitrotetrazolium blue color-
metric substrate (R&D Systems). The positive cutoff
alue was calculated as the mean  3 SD of the 3
egative controls included in each run. This method was
alidated against a commercially available HHV-7 indi-
ect immunoﬂuorescence kit (Advanced Biotechnologies
nc.). Runs were considered valid if the negative and
ositive controls performed within the expected range,
e, negative controls, OD 0.2; low positive controls,
D 0.5 to 1; and high positive controls, OD 1.5.
tatistical Methods
Rates of infection and 95% conﬁdence intervals
CI) were calculated on the basis of the binomial
istribution.
ESULTS
The study was conducted on 362 randomly se-
ected CB aliquots. IgG antibody testing of the ma-
CR
Probe 5= 3 3=
ATT CGT GGT CGT GGC CAA CTG GTG CTG CCG
GTC GCG CTT A
CCG CGG GAG CTA GGG GCA GG
AAC TGT CTG ACT GGC AAA AAC TTT T
AGA ATT CTG TAC CCAT GGG CAC ATT TGT AC
CCA TGG TCG TGC CGC AGC Altiplex Pernal and/or cord sera revealed that 187 mothers
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Herpesvirus Infections of Cord Blood Cells
Bere CMV seropositive, 300 were EBV seropositive,
97 were HHV-6 seropositive, 335 were HHV-7 se-
opositive, and 16 were HHV-8 seropositive (Table
). Two CB samples contained HHV-6 DNA. No
ther HHV DNA was found. The incidence of
HV-6 infection of CB cells was 0.67% (95% CI,
.08%-2.4%) among samples obtained from seropos-
tive mothers. The overall incidence of HHV-6 infec-
ion of CB was 0.55% (95% CI, 0.07%-1.98%). The
ncidences of other HHV infections of CB were null,
ith overall 95% CIs of 0% to 1%. However, the
pper limit of the 95% CI adjusted for seropositivity
aried from 1.1% for HHV-7 to 20.6% for HHV-8.
he latter reﬂected the low HHV-8 seroprevalence in
ur CB donor population.
ISCUSSION
This study showed that HHV-6 infection of CB
ccurred in 0.55% of banked samples obtained from
HV-6–seropositive mothers (95% CI, 0.1%-2%).
he presence of HHV-6 DNA in the specimen that
enerates the graft indicates that there is a risk of
ransmission of the virus to the CB recipient. The risk
f CB-mediated HHV-6 transmission is also sup-
orted by previous studies that showed higher HHV-6
iral loads in CB recipients compared with other types
f stem cell transplants and found evidence of primary
HV-6 infection after CB transplantation [18].
HV-6 infection in allogeneic CB recipients is asso-
iated with clinical manifestations ranging from fever
nd rash to encephalitis, pneumonitis, and bone mar-
ow suppression [6,19-23]. CB transplantation is more
ikely to be used in childhood and to introduce the
irus to the host for the ﬁrst time. It has also been
emonstrated that CB recipients use their prior im-
unologic memory to reconstitute immune responses
24]. When faced with a primary infection after trans-
lantation, the host will not be able to use immuno-
ogic memory to develop a protective response against
HV-6. Whether this might impair the ability of the
able 2. Incidence of  and  Human Herpesvirus Infections in 362
ord Blood Samples
Virus
Ab
pos
PCR
pos
% Rate of Infection
(95% Confidence Interval)
Seropositive Overall
HV-6 297 2 0.67 (0.08-2.41) 0.55 (0.07-1.98)
HV-7 335 0 0 (0-1.1) 0 (0-1.01)
MV 187 0 0 (0-1.95) 0 (0-1.01)
BV 300 0 0 (0-1.22) 0 (0-1.01)
HV-8 16 0 0 (0-20.59) 0 (0-1.01)
b indicates antibodies; CMV, cytomegalovirus; EBV, Epstein-
Barr virus; HHV, human herpesvirus; PCR, polymerase chain
reaction; pos, positive.ost to mount a competent immune response remains i
B&MTo be determined. A conservative approach at this
oint would be to avoid using HHV-6 PCR-positive
B samples whenever possible.
The incidence of CMV infection was 0% (95%
I, 0%-1%) in the CB units obtained from CMV
gM-negative pregnancies, even though the overall
ncidence of congenital CMV infection in the United
tates varies between 1% and 2% [25]. This is con-
istent with previous reports that the presence of
MV IgM in the serum of pregnant women identiﬁes
ost cases at risk of in utero CMV transmission [26].
urthermore, CMV PCR of the CB or infant’s blood
s invariably positive in cases of congenital CMV in-
ection [27]. Taken together, this indicates that ex-
luding CB donations from CMV IgM–seropositive
others is an effective measure to prevent CB-asso-
iated CMV transmission and could potentially be
mbraced by other centers, which currently do not
outinely test pregnant volunteers for CMV IgM. Our
B bank routinely screens all CB by CMV PCR
efore clinical use. Since October 1996, out of 312 CB
amples screened in this fashion, only 1 had a positive
esult. Adding these numbers to the results of the 362
B samples tested in this study shows a composite risk
f CB infection with CMV of 0.15% (95%CI, 0.04%-
.82%), which further underscores the effectiveness of
he CMV IgM screening procedure.
There were no cases of EBV, HHV-7, or HHV-8
nfections of the CB units. EBV de novo infection
eading to posttransplantation lymphoproliferative
isorder has been described after bone marrow trans-
lantation [8], but not after CB transplantation. This
s consistent with the absence of EBV DNA in CB
nits and with the extremely low incidence of congen-
tal EBV infection [28]. HHV-7 has been less studied
n the setting of CB. Although HHV-7 shares many
pidemiologic and clinical characteristics with HHV-6
nd CMV, HHV-7 reactivations seem to be less fre-
uent than those of other  HHVs, both in pregnancy
29] and in CB recipients [30]. Furthermore, HHV-7 has
ot yet been associated with symptomatic disease in CB
ecipients, thus indicating that screening CB for HHV-7
nfection might not be necessary. HHV-8 has been re-
orted as the cause of fatal bone marrow failure in an
utologous stem cell recipient [7] and therefore deserves
pecial attention in other transplantation settings. In
tero transmission of HHV-8 is less than 1% in endemic
reas [13]. This, coupled with the low seroprevalence of
HV-8 in our environment, explains the absence of
HV-8 infection in our CB samples.
Patients undergoing CB transplantation beneﬁt
rom a low incidence of graft-versus-host disease but
ight experience more frequent infectious complica-
ions. Among  and  HHVs, HHV-6 and CMV
equire CB screening, but HHV-7 and EBV do not.
HV-8 infection of CB seems to be a minor problemn areas of low seroprevalence, but it needs to be
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3urther studied in highly endemic areas. Other poten-
ial CB infections, including parvovirus B19, rubella,
nd toxoplasmosis—as well as Chagas disease and ma-
aria in endemic areas—also need to be studied.
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